Related references
Note: Only part of the references are listed.RAS-mediated oncogenic signaling pathways in human malignancies
Abdul Q. Khan et al.
SEMINARS IN CANCER BIOLOGY (2019)
An Integrated Global Analysis of Compartmentalized HRAS Signaling
Tapesh Santra et al.
CELL REPORTS (2019)
Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation
Theodosia Charitou et al.
BRITISH JOURNAL OF CANCER (2019)
Tissue-Specific Oncogenic Activity of KRASA146T
Emily J. Poulin et al.
CANCER DISCOVERY (2019)
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer
Tamuro Hayama et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2019)
Role of protein kinase CK2 in antitumor drug resistance
Christian Borgo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Chao Yan et al.
PHARMACOLOGICAL REVIEWS (2018)
KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer
Stephane Renaud et al.
CLINICAL LUNG CANCER (2018)
A model for RAS mutation patterns in cancers: finding the sweet spot
Siqi Li et al.
NATURE REVIEWS CANCER (2018)
Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and lsocitrate Dehydrogenase (IDH1) Driven Astrocytoma
Sophia Doll et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice
Feng-Hsiang Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab
Ondrej Fiala et al.
TUMOR BIOLOGY (2016)
Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells
Christian Posch et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
Barbara Bournet et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
Laura Brunelli et al.
SCIENTIFIC REPORTS (2016)
Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
Dean E. Hammond et al.
JOURNAL OF PROTEOME RESEARCH (2015)
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer
Wouter W. Mellema et al.
LUNG CANCER (2015)
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
John C. Hunter et al.
MOLECULAR CANCER RESEARCH (2015)
KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells
Dominic Leiser et al.
MOLECULAR ONCOLOGY (2015)
Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines
Britta Stolze et al.
SCIENTIFIC REPORTS (2015)
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR
Linara Gabitova et al.
CELL REPORTS (2015)
Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis
Georgios Antonios Margonis et al.
JAMA SURGERY (2015)
Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach
Wei Jiang et al.
ONCOTARGET (2015)
Molecular Pathways: Targeting RAC-p21-Activated Serine-Threonine Kinase Signaling in RAS-Driven Cancers
Nicole M. Baker et al.
CLINICAL CANCER RESEARCH (2014)
Cholesterol and Cancer, in the Balance
Sandrine Silvente-Poirot et al.
SCIENCE (2014)
Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma
Christin E. Burd et al.
CANCER DISCOVERY (2014)
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
Laura Brunelli et al.
ONCOTARGET (2014)
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
Stefan Boeck et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Dclk1 distinguishes between tumor and normal stem cells in the intestine
Yuki Nakanishi et al.
NATURE GENETICS (2013)
KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials
Fausto Petrelli et al.
MEDICAL ONCOLOGY (2013)
The Role of the PI3K-AKT Pathway in Melanoma
Michael A. Davies
CANCER JOURNAL (2012)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
Sabine Tejpar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis
C. A. Whipple et al.
ONCOGENE (2012)
DCLK I immunoreactivity in colorectal neoplasia
Giuseppe Gagliardi et al.
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY (2012)
Carbon metabolism and the sign of control coefficients in metabolic adaptations underlying K-ras transformation
Pedro de Atauri et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2011)
RAS oncogenes: weaving a tumorigenic web
Yuliya Pylayeva-Gupta et al.
NATURE REVIEWS CANCER (2011)
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine
G. Smith et al.
BRITISH JOURNAL OF CANCER (2010)
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Manickam Janakiraman et al.
CANCER RESEARCH (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Control of Cell Survival and Proliferation by Mammalian Eukaryotic Initiation Factor 4B
David Shahbazian et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients
Jeffrey W. Tyner et al.
BLOOD (2009)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Subtypes of breast cancer show preferential site of relapse
Marcel Smid et al.
CANCER RESEARCH (2008)
Distinct functions of H-Ras and K-Ras in proliferation and survival of primary hepatocytes due to selective activation of ERK and PI3K
Carola M. Rosseland et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
Kevin M. Haigis et al.
NATURE GENETICS (2008)
Ras oncogenes: split personalities
Antoine E. Karnoub et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Ras proteins: paradigms for compartmentalised and isoform-specific signalling
J. Omerovic et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
Characterization of a novel oncogenic K-ras mutation in colon cancer
Kiwamu Akagi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12
Maria Virtudes Cespedes et al.
CARCINOGENESIS (2006)
Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors
Oliver Rocks et al.
CURRENT OPINION IN CELL BIOLOGY (2006)
Gene expression profiling of breast cell lines identifies potential new basal markers
E Charafe-Jauffret et al.
ONCOGENE (2006)
Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line
ML Roberts et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis
TG Bivona et al.
MOLECULAR CELL (2006)
Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation
D Matallanas et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice
N Potenza et al.
EMBO REPORTS (2005)
Ras signalling on the endoplasmic reticulum and the Golgi
VK Chiu et al.
NATURE CELL BIOLOGY (2002)
Differential activation of the pac pathway by Ha-Ras and K-Ras
AB Walsh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development
LM Esteban et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma
K Tsukuda et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Share Paper
